We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics Extends Deal With Roche for Two New Studies
Read MoreHide Full Article
Immunomedics Inc. announced that it will extend its clinical collaboration with Roche (RHHBY - Free Report) with two new studies evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) of the former and the latter’s Tecentriq (atezolizumab) in patients with metastatic urothelial cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC). Tecentriq is Roche’s programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI).
Immunomedics already collaborated with Roche in 2019 to develop Trodelvyin for the frontline setting of triple-negative breast cancer (mTNBC) in combination with the latter’s Tecentriq.
Shares of the company have increased 88.9% year to date compared with the industry’s growth of 6.4%.
We remind investors that in April 2020, Trodelvy obtained accelerated approval from the FDA for the treatment of adult patients with metastatic mTNBC, who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for previously-treated mTNBC and also the first FDA-approved anti-Trop-2 ADC.
Per the agreement, Roche will conduct two open-label, randomized phase Ib/II studies using its MORPHEUS platform.
MORPHEUS-mUC will randomize checkpoint inhibitor (CPI)-naive mUC patients who have failed to respond to platinum-based chemotherapy to receive either the Tecentriq plus Trodelvy combination or Tecentriq alone.
The second study-MORPHEUS-Lung will randomize CPI-experienced mNSCLC patients who failed to respond to platinum-based regimens to receive either the Tecentriq and Trodelvy combo or docetaxel alone.
Further, Immunomedics announced that the new phase II NeoSTAR study enrolled the first patient with localized TNBC to receive Trodelvy before surgery to remove the tumor. The primary endpoint of this study is pathological complete response rate while disease-free survival and overall survival are the secondary endpoints.
We remind investors that Immunomedics also collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Immunomedics Extends Deal With Roche for Two New Studies
Immunomedics Inc. announced that it will extend its clinical collaboration with Roche (RHHBY - Free Report) with two new studies evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) of the former and the latter’s Tecentriq (atezolizumab) in patients with metastatic urothelial cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC). Tecentriq is Roche’s programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI).
Immunomedics already collaborated with Roche in 2019 to develop Trodelvyin for the frontline setting of triple-negative breast cancer (mTNBC) in combination with the latter’s Tecentriq.
Shares of the company have increased 88.9% year to date compared with the industry’s growth of 6.4%.
We remind investors that in April 2020, Trodelvy obtained accelerated approval from the FDA for the treatment of adult patients with metastatic mTNBC, who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for previously-treated mTNBC and also the first FDA-approved anti-Trop-2 ADC.
Per the agreement, Roche will conduct two open-label, randomized phase Ib/II studies using its MORPHEUS platform.
MORPHEUS-mUC will randomize checkpoint inhibitor (CPI)-naive mUC patients who have failed to respond to platinum-based chemotherapy to receive either the Tecentriq plus Trodelvy combination or Tecentriq alone.
The second study-MORPHEUS-Lung will randomize CPI-experienced mNSCLC patients who failed to respond to platinum-based regimens to receive either the Tecentriq and Trodelvy combo or docetaxel alone.
Further, Immunomedics announced that the new phase II NeoSTAR study enrolled the first patient with localized TNBC to receive Trodelvy before surgery to remove the tumor. The primary endpoint of this study is pathological complete response rate while disease-free survival and overall survival are the secondary endpoints.
We remind investors that Immunomedics also collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
Immunomedics currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Immunomedics, Inc. Price
Immunomedics, Inc. price | Immunomedics, Inc. Quote
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>